ONCAlert | AstraZeneca: Pioneers in Ovarian Cancer

Latest NewsMORE >>

Based on positive progression-free survival results from the PACIFIC trial, a supplemental biologics license application for durvalumab (Imfinzi) for the treatment of patients with stage III, unresectable non–small cell lung cancer has been granted a priority review by the FDA.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.